Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 12/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6901262 | 0.76 | PTGES (0.52) | ALDH1A1MAPK1CYP3A4CYP2D6TSHR | |
| SCHEMBL1736579 | 0.74 | JAK2 (0.50) | KCNH2HRH3ALDH1A1MAPK1USP2 | |
| SCHEMBL6899514 | 0.73 | L3MBTL1 (0.54) | LMNA | |
| SCHEMBL206944 | 0.73 | VCP (0.64) | ALDH1A1CYP1A2LMNA | |
| SCHEMBL205560 | 0.73 | VCP (0.64) | ALDH1A1CYP1A2LMNA | |
| SCHEMBL28141538 | 0.72 | LTA4H (0.56) | KCNH2HRH3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28142366 | 0.72 | LTA4H (0.56) | KCNH2HRH3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7057377 | 0.72 | DYRK3 (0.54) | KCNH2HRH3ALDH1A1MAPK1USP2 | |
| SCHEMBL30682518 | 0.71 | LTA4H (0.58) | HRH3FAAHCYP3A4CYP2D6TSHR | |
| SCHEMBL28158844 | 0.71 | SYK (0.59) | KCNH2HRH3ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1635890-A | Neuroprotective 2-pyridinamine compositions and related methods | ORTHO MCNEIL PHARM INC (US) | 2005-07-06 | — | — | CN | claimed |
| JP-2004510707-A | — | — | 2004-04-08 | — | — | JP | claimed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | claimed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| CN-1635890-A | Neuroprotective 2-pyridinamine compositions and related methods | ORTHO MCNEIL PHARM INC (US) | 2005-07-06 | — | — | CN | disclosed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | KCNH2 703/4885HRH3 651/4885ALDH1A1 1986/4885 |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | KCNH2 703/4885HRH3 651/4885ALDH1A1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.